TY - JOUR
T1 - Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer
AU - Drescher, Kristen M.
AU - Sharma, Poonam
AU - Watson, Patrice
AU - Gatalica, Zoran
AU - Thibodeau, Stephen N.
AU - Lynch, Henry T.
N1 - Funding Information:
Acknowledgments Grant support This research was supported by revenue from Nebraska Cigarette Taxes awarded to Creighton University by the Nebraska, Department of Health and Human Services (LB 595; KMD, HTL). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the State of Nebraska or the Nebraska Department of Health and Human Services. The National Institutes of Health Early Detection Research Network Grant #1U01CA86389 also provided support for these studies. Dr. Henry Lynch holds the Charles F. and Mary C. Heider Chair in Cancer Research at Creighton University. This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program (1 C06 RR17417-01) from the National Center for Research Resources, National Institutes of Health.
PY - 2009/9
Y1 - 2009/9
N2 - The ability of the host to mount an appropriate immune response to aberrant cells is one factor that determines prognosis in cancer patients. Naturally occurring regulatory T cells (T regs; CD4+ CD25+ cells) are key regulators of peripheral tolerance. It has been suggested that high levels of T regs are detrimental to the patient in some forms of cancer, but the role of these antigen-specific cells in individuals with colorectal cancers with high levels of microsatellite instability is unknown. Herein, we examined the ability of individuals with MSI-H or microsatellite stable colon cancer to recruit lymphocytes to the tumor site. Immunohistochemical staining was performed on archived paraffin-embedded specimens from a total of 38 individuals with MSI-H (n = 25) or MSS (n = 13) colon cancers to determine the proportion of CD3+, CD8+ and CD25+ cells infiltrating the tumor site. Patients with MSI-H colon cancers had increased percentages of CD8+ TILs (cytotoxic T cells) as compared to individuals with MSS colon cancer (47.3 vs. 24.04% of the infiltrate CD8+, respectively). No differences in the levels of CD25+ T cells were observed between individuals with MSI-H colon cancers and MSS colon cancers (0.53 vs. 0.54% CD25+, respectively). Together, these data suggest that the survival advantage enjoyed by patients with MSI-H colorectal cancer may, in part, be attributed to the increased cytolytic response, but not to an antigen-specific immunosuppressive response in MSS patients.
AB - The ability of the host to mount an appropriate immune response to aberrant cells is one factor that determines prognosis in cancer patients. Naturally occurring regulatory T cells (T regs; CD4+ CD25+ cells) are key regulators of peripheral tolerance. It has been suggested that high levels of T regs are detrimental to the patient in some forms of cancer, but the role of these antigen-specific cells in individuals with colorectal cancers with high levels of microsatellite instability is unknown. Herein, we examined the ability of individuals with MSI-H or microsatellite stable colon cancer to recruit lymphocytes to the tumor site. Immunohistochemical staining was performed on archived paraffin-embedded specimens from a total of 38 individuals with MSI-H (n = 25) or MSS (n = 13) colon cancers to determine the proportion of CD3+, CD8+ and CD25+ cells infiltrating the tumor site. Patients with MSI-H colon cancers had increased percentages of CD8+ TILs (cytotoxic T cells) as compared to individuals with MSS colon cancer (47.3 vs. 24.04% of the infiltrate CD8+, respectively). No differences in the levels of CD25+ T cells were observed between individuals with MSI-H colon cancers and MSS colon cancers (0.53 vs. 0.54% CD25+, respectively). Together, these data suggest that the survival advantage enjoyed by patients with MSI-H colorectal cancer may, in part, be attributed to the increased cytolytic response, but not to an antigen-specific immunosuppressive response in MSS patients.
UR - http://www.scopus.com/inward/record.url?scp=68449099031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68449099031&partnerID=8YFLogxK
U2 - 10.1007/s10689-009-9233-0
DO - 10.1007/s10689-009-9233-0
M3 - Article
C2 - 19165625
AN - SCOPUS:68449099031
VL - 8
SP - 231
EP - 239
JO - Familial Cancer
JF - Familial Cancer
SN - 1389-9600
IS - 3
ER -